Carsten Denkert
Papers
2
Total Citations
42
H-Index
2
About
Carsten Denkert is a leading pathologist and translational cancer researcher whose work bridges molecular diagnostics and immunotherapy response prediction. His primary research areas include ovarian cancer biomarkers, breast cancer molecular subtyping, and tumor immune microenvironment analysis. Denkert has made pivotal contributions to the clinical implementation of homologous recombination deficiency (HRD) testing in ovarian carcinoma, demonstrating through a real-world cohort of 514 samples how next-generation sequencing of BRCA1/BRCA2 and over 26,000 single-nucleotide polymorphisms can guide targeted therapy strategies. His landmark 2011 GeparQuinto-PREDICT substudy prospectively validated an RNA-based molecular tumor typing system using ESR1 and HER2 expression in FFPE tissue, while also establishing standardized cutoffs for assessing intratumoral and stromal lymphocytes as predictors of neoadjuvant chemotherapy response. With over 40 citations on his HRD work alone and foundational contributions to immune infiltration quantification, Denkert’s research has directly shaped precision oncology protocols. His achievements include developing clinically adopted diagnostic frameworks that enable pathologists to identify patients most likely to benefit from PARP inhibitors and immunotherapy, making him a key figure in the molecular pathology of gynecologic and breast cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2